Summary: At Psych Congress 2024, Axsome Therapeutics will present new research on solriamfetol, focusing on its effectiveness for managing excessive daytime sleepiness and cognitive impairment in patients with obstructive sleep apnea (OSA) and narcolepsy. These studies, part of … [Read more...]